The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations

Laura J. Vella; Miles C. Andrews; Anupama Pasam; Katherine Woods; Andreas Behren; Jonathan S. Cebon

doi:10.4161/21624011.2014.946367

The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations

Laura J. Vella, Miles C. Andrews, Anupama Pasam, Katherine Woods, Andreas Behren, Jonathan S. Cebon

Research output: Contribution to journal › Article › Other › peer-review

11 Citations (Scopus)

Abstract

Metastatic melanoma is frequently fatal. Optimal treatment regimens require both rapid and durable disease control, likely best achieved by combining targeted agents with immunotherapeutics. In order to accomplish this, a detailed understanding of the immune consequences of the kinase inhibitors used to treat melanoma is required.

Original language	English
Article number	e946367
Number of pages	3
Journal	OncoImmunology
Volume	3
Issue number	7
DOIs	https://doi.org/10.4161/21624011.2014.946367
Publication status	Published - 1 Jan 2014
Externally published	Yes

Keywords

BRAF
Dendritic cells
MEK
Melanoma
T-lymphocytes

Access to Document

10.4161/21624011.2014.946367

Cite this

@article{f749445790a648f0a6c1789aa9d0d845,

title = "The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations",

abstract = "Metastatic melanoma is frequently fatal. Optimal treatment regimens require both rapid and durable disease control, likely best achieved by combining targeted agents with immunotherapeutics. In order to accomplish this, a detailed understanding of the immune consequences of the kinase inhibitors used to treat melanoma is required.",

keywords = "BRAF, Dendritic cells, MEK, Melanoma, T-lymphocytes",

author = "Vella, {Laura J.} and Andrews, {Miles C.} and Anupama Pasam and Katherine Woods and Andreas Behren and Cebon, {Jonathan S.}",

year = "2014",

month = jan,

day = "1",

doi = "10.4161/21624011.2014.946367",

language = "English",

volume = "3",

journal = "OncoImmunology",

issn = "2162-402X",

publisher = "Taylor & Francis",

number = "7",

}

TY - JOUR

T1 - The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations

AU - Vella, Laura J.

AU - Andrews, Miles C.

AU - Pasam, Anupama

AU - Woods, Katherine

AU - Behren, Andreas

AU - Cebon, Jonathan S.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Metastatic melanoma is frequently fatal. Optimal treatment regimens require both rapid and durable disease control, likely best achieved by combining targeted agents with immunotherapeutics. In order to accomplish this, a detailed understanding of the immune consequences of the kinase inhibitors used to treat melanoma is required.

AB - Metastatic melanoma is frequently fatal. Optimal treatment regimens require both rapid and durable disease control, likely best achieved by combining targeted agents with immunotherapeutics. In order to accomplish this, a detailed understanding of the immune consequences of the kinase inhibitors used to treat melanoma is required.

KW - BRAF

KW - Dendritic cells

KW - MEK

KW - Melanoma

KW - T-lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=84911408582&partnerID=8YFLogxK

U2 - 10.4161/21624011.2014.946367

DO - 10.4161/21624011.2014.946367

M3 - Article

AN - SCOPUS:84911408582

SN - 2162-402X

VL - 3

JO - OncoImmunology

JF - OncoImmunology

IS - 7

M1 - e946367

ER -

The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations

Abstract

Keywords

Access to Document

Other files and links

Cite this